Search Results 1661-1670 of 19432 for hemoglobin

1. A Study to Continue to Evaluate the Safety and Clinical Performance of the MOMENTUM 3 Left Ventricle Assist System

   Plasma-free hemoglobin (PfHb) and modified index of hemolysis (MIH) were compared with HeartMate II (HMII). CFD showed secondary flow path residence times ...

2. Neoadjuvant dual checkpoint blockade with PD1 and LAG-3 inhibition in resectable Non-small cell lung Cancer - Mayo Clinic

   Hemoglobin ≥ 8.0 g/dL; Absolute neutrophil count (ANC) ≥ 1500/mm3; Platelet count ≥ 100,000/mm3; Total bilirubin ≤ 1.5 x ULN; Alanine aminotransferase (ALT) ...

3. A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Renal Function - Mayo Clinic

   Hemoglobin ≥ 7.0 g/dL;; Platelets ≥ 50 x 10^9/L;; Total bilirubin ≤ 1.5 x Upper limit of normal (ULN) (Isolated bilirubin ≥ 1.5 x ULN is acceptable if ...

4. A Study to Test Adding Pembrolizumab to Olaparib Alone as Therapy for Patients with Pancreatic Cancer That Has Spread with Inherited BRCA Mutations - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL. Patients must have CA19-9 obtained within 42 days prior to registration. Patients must be able to swallow and retain oral ...

5. LEVosimendan To Improve Exercise Limitation In Patients With PH-HFpEF - Mayo Clinic

   Hemoglobin <10 g/dL per local laboratory. 2. Serum alanine aminotransferase or aspartate aminotransferase levels > 3 × upper limit of normal (ULN) or total ...

6. A Study to Evaluate AL101 Monotherapy in Patients with Notch Activated Triple Negative Breast Cancer - Mayo Clinic

   hemoglobin < 8 g/dL;; total bilirubin > 1.5 upper limit of normal (ULN) (except known Gilbert's syndrome whereby the total bilirubin must be < 5 mg/dL); ...

7. A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma - Mayo Clinic

   Hemoglobin 9 g/dL. Acceptable blood sugar control: Fasting glucose < 160 mg/dL (CTCAE grade 1 baseline). Urinalysis: No clinically significant abnormalities ...

8. A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT - Mayo Clinic

   - Hemoglobin ≥ 8.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days prior to enrollment). - Creatinine clearance or radioisotope ...

9. A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 21 days;; Serum creatinine ≤ 1.5 x upper limit of normal (ULN); ...

10. A Phase 2, Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence - Mayo Clinic

    No subjects with an interval ≥ 42 days between hemoglobin measurements will be enrolled;; There must not be any RBC transfusions within the 84-day period ...